Butyrylcholinesterase as a prognostic marker: A review of the literature

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 1, 2013, Pages 31-39

  Santarpia, Lidia ^a   Grandone, Ilenia ^a   Contaldo, Franco ^a   Pasanisi, Fabrizio ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Butyrylcholinesterase; Liver and nonliver diseases; Obesity; Prognostic marker; Protein energy malnutrition

Indexed keywords

CHOLESTEROL; CHOLINESTERASE; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ANOREXIA NERVOSA; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; ENTERITIS; ENZYME ACTIVITY; GERIATRICS; HELLP SYNDROME; HEMODIALYSIS; HUMAN; INFLAMMATION; LIVER CELL DAMAGE; LIVER DISEASE; METABOLIC SYNDROME X; NUTRITIONAL SUPPORT; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CALORIE MALNUTRITION; PROTEIN SYNTHESIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84874519163     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-012-0083-5     Document Type: Review

References (73)

1. Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia. 1997; 52: 244-60.
2. Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT. Half-life of plasma cholinesterase. Acta Anaesthesiol Scand. 1988; 32: 266-9.
3. Pan Y, Muzyka JL, Zhan CG. Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation. J Phys Chem B. 2009; 113: 6543-52.
4. Paes AM, Carniatto SR, Francisco FA, Brito NA, Mathias PC. Acetylcholinesterase activity changes on visceral organs of VMH lesion-induced obese rats. Int J Neurosci. 2006; 116: 1295-302.
5. Cucuianu M, Nistor T, Hâncu N, Orbai P, Muscurel C, Stoian I. Serum cholinesterase activity correlates with serum insulin, C-peptide and free fatty acids levels in patients with type 2 diabetes. Rom J Intern Med. 2002; 40: 43-51.
6. Kutty KM, Payne RH. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal. 1994; 8: 247-50.
7. Rosenman KD, Guss PS. Prevalence of congenital deficiency in serum cholinesterase. Arch Environ Health. 1997; 52: 42-4.
8. Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol. 2012; 11: 356-63.
9. Das UN. Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation. Ann Hepatol. 2012; 11: 409-11.
10. Burritt MF, Anderson CF. Laboratory assessment of nutritional status. Hum Pathol. 1984; 15: 130-3.
11. Jensen GL, Mirtallo J, Compher C, Dhaliwal R, Forbes A, Grijalba RF, et al. International Consensus Guideline Committee. Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J Parenter Enteral Nutr. 2010; 34(: 156-9.
12. Buchanan JB, Johnson RW. Regulation of food intake by inflammatory cytokines in the brain. Neuroendocrinology. 2007; 86: 183-90.
13. Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. J Am Diet Assoc. 2004; 104: 1258-64.
14. Soeters PB, Schols AM. Advances in understanding and assessing malnutrition. Curr Opin Clin Nutr Metab Care. 2009; 12: 487-94.
15. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008; 64: 895-900.
16. Dabke AT, Pohowalla JN, Inamdar S, Singh SD, Mathur PS. Serum cholinesterase and histopathology of the liver in severe protein calorie malnutrition. Indian J Pediatr. 1972; 39: 151-7.
17. Montgomery RD. The relation of oedema to serum protein and pseudocholinesterase levels in the malnourished infant. Arch Dis Childr. 1963; 38: 343.
18. Camarero González E, et al. Protein-energy malnutrition: its effects on 4 metabolic parameters. Nutr Hosp. 1995; 10: 158-60.
19. Abou-Hatab K, O'Mahony MS, Patel S, Woodhouse K. Relationship between age and plasma esterases. Age Ageing. 2001; 30: 41-5.
20. Seiler WO, Stahelin HB. Special aspects of malnutrition in geriatrics. Schweiz Med Wochenschr. 1995; 125: 149-58.
21. Mitrache C, Passweg JR, Libura J, Petrikkos L, Seiler WO, Gratwoh A, et al. Anemia: an indicator for malnutrition in the elderly. Ann Hematol. 2001; 80: 295-8.
22. Shan-Zhi G, et al. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastrenterol. 2005; 11: 4604-6.
23. Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non liver disease aberration in liver function tests. Pathophysiology. 2006; 13: 91-3.
24. Santarpia L, Alfonsi L, Pasanisi F, De Caprio C, Scalfi L, Contaldo F. Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition. 2006; 22: 355-60.
25. Ravera E, Bozzetti F, Radaelli G. Predictability of deterioration in marginally malnourished cancer patients during hospitalization. Clin Nutr. 1989; 8: 203-6.
26. Chougule A, Hussain S, Agarwal DP. Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase and serum alanine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther. 2008; 4: 21-519.
27. Bozzetti F. Effects of artificial nutrition on the nutritional status of cancer patients. J Parenter Enteral Nutr. 1989; 13: 406-20.
28. Bozzetti F, Boracchi P, Costa A, Cozzaglio L, Battista A, Giori A, et al. Relationship between nutritional status and tumor growth in humans. Tumori. 1995; 81: 1-6.
29. Mitsunaga S, et al. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas. 2008; 36: 241-8.
30. Guarnieri G, Faccini L, Lipartiti T, et al. Simple methods for nutritional assessment in hemodialyzed patients. Am J Clin Nutr. 1980; 33: 1598-607.
31. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998; 31: 93-100.
32. Novacek G, et al. Are single measurements of pseudocholinesterase and albumin markers for inflammatory activity or nutritional status in Crohn's disease? Wien Klin Wochenschr. 1993; 105: 111-5.
33. Khalil SN, Dudrick SJ, Mathieu A, Rigor Sr BM, Fody EP. Low level of pseudocholinesterase in patients with Crohn's disease. Lancet. 1980; 2: 267-8.
34. Sologub VK, Zaets TL, Tarasov AV, Mordkovitch MR, Yashin AY. Enteral hyperalimentation of burned patients: the possibility of correcting metabolic disorders by the early administration of prolonged high calorie evenly distributed tube feeds. Burns. 1992; 18: 245-9.
35. Kanai et al. Liver function tests in patients with bacteremia. J Clin Lab Anal 2006: 66-9.
36. Weismüller TJ et al. A prediction of outcome would improve preoperative patient selection and management. Scand J Gastroenterol. 2008.
37. Di Pascoli L, Lion A, Milazzo D, Caregaro L. Acute liver damage in anorexia nervosa. Int J Eat Disord. 2004; 36: 114-7.
38. De Caprio C, Alfano A, Senatore I, Zarrella L, Pasanisi F, Contaldo F. Severe acute liver damage in anorexia nervosa: two case reports. Nutrition. 2006; 22: 572-5.
39. Montagnese C. Cholinesterase and other serum liver enzymes in underweight outpatients with eating disorders. Int J Eat Disord. 2007; 40: 746-50.
40. Donini LM, Savina C, Ricciardi LM, Coletti C, Paolini M, Scavone L, et al. Predicting the outcome of artificial nutrition by clinical and functional indices. Nutrition. 2009; 25: 11-9.
41. Grandone L, Santarpia L, Alfonsi L, Pagano MC, Pasanisi F, Contaldo F. Serum cholinesterase as indicator of parenteral nutrition efficacy in protein energy malnutrition: four case reports. e-SPEN (The European e-Journal of Clinical Nutrition and Metabolism) - 18 November 2009 (10. 1016/j. eclnm. 2009. 10. 006).
42. Fieber SS. Pseudocholinesterase-a clinical assessment. Crit Care Med. 1981; 9: 660-1.
43. Robinson MK, Trujillo EB, Mogensen KM, Rounds J, McManus K, Jacobs DO. Improving nutritional screening of hospitalized patients: the role of prealbumin. JPEN. 2003; 27: 389-95.
44. Hamamoto S, et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol. 2005; 20: 204-8.
45. Sportiello V, Pace M, Fernandes D, Stefan C. Serum levels of pseudocholinesterase in alcoholic cirrhosis patients. Correlation with the extent of anatomo-functional damage. Unfavorable prognostic index. Arch Sci Med (Torino). 1981; 138: 307-13.
46. Ott M, et al. Intestinal absorption and malnutrition in patients with the acquired immunodeficiency syndrome (AIDS). Gastroenterol Z. 1993; 31: 661-5.
47. Lurie S. Pseudocholinesterase deficiency associated with HELLP syndrome. Am J Perinatol. 2004; 21: 315-7.
48. Lurie S. Reduced pseudocholinesterase activity in patients with HELLP syndrome. Reprod Sci. 2007; 14: 192-6.
49. Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem. 2005; 38: 799-805.
50. Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem. 2006; 52: 845-52.
51. Menache R, Kenda L, Shaked P, Schwartzman S, Lewinski U. The prognostic value of serum acetylcholinesterase in myocardial infarction. Theoretical and clinical considerations. Res Exp Med (Berl). 1982; 181: 181-7.
52. Popescu TA, Fekete T, Popescu E, Böjthy I, Laszlo M. Serum pseudocholinesterase activity during experimental fattening. Med Interne. 1976; 14: 71-3.
53. Kutty KM, Huang SN, Kean KT. Pseudocholinesterase in obesity: hypercaloric diet induced changes in experimental obese mice. Experientia. 1981; 37: 1141-2.
54. Kean KT, Kutty KM, Huang SN, Jain R. A study of pseudocholinesterase induction in experimental obesity. J Am Coll Nutr. 1986; 5: 253-61.
55. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond). 1993; 85: 77-81.
56. Valle A, O'Connor DT, Taylor P, Zhu G, Montgomery GW, Slagboom PE, et al. Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem. 2006; 52: 1014-20.
57. Alcantara VM, Oliveira LC, Rea RR, Suplicy HL, Chautard-Freire-Maia EA. Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med. 2005; 43: 285-8.
58. Annapurna V, Senciall I, Davis AJ, Kutty KM. Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia. 1991; 34: 320-4.
59. Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJ, Heine RJ. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus? Clin Sci (Lond). 2001; 101: 29-35.
60. Iwasaki T, Yoneda M, Nakajima A, Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med. 2007; 46: 1633-9.
61. Chu MI, Fontaine P, Kutty KM, Murphy D, Redheendran R. Cholinesterase in serum and low density lipoprotein of hyperlipidemic patients. Clin Chim Acta. 1978; 85: 55-9.
62. Jain R, Kutty KM, Huang SN, et al. Pseudocholinesterase/high-density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem. 1983; 29: 1031-3.
63. Kutty KM, Jain R, Huang S, Kean K. Serum pseudocholinesterase: high density lipoprotein cholesterol ratio as an index of risk for cardiovascular disease. Clin Chim Acta. 1981; 115: 55-61.
64. Iwasaki M, Takada Y, Hayashi M, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation. 2004; 78: 1501-5.
65. Cucuianu M, Popescu TA, Haragus A. Pseudocholinesterase in obese and hyperlipidaemic subjects. Clin Chim Acta. 1968; 22: 151-5.
66. Cucuianu M, Popescu TA, Opincaru A, Haragus S. Serum pseudocholinesterase and ceruloplasmine in various types of hyperlipoproteinaemia. Clin Chim Acta. 1975; 59: 19-27.
67. Jain R, Kutty KM, Huang S, Kean K. Pseudocholinesterase high density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem. 1983; 29: 1031-3.
68. Lehtonen A, Marniemi J, Ingberg M, Maatela J, Alanen E, Niittymaski K. Levels of serum lipids, apolipoproteins A-1 and B, and pseudocholinesterase activity and their discriminative value in patients with coronary by-pass operation. Atherosclerosis. 1986; 59: 215-21.
69. Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y, et al. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol. 1986; 8: 599-602.
70. Cucuianu M, Opincaru A, Tapalagǎ D. Similar behaviour of lecithin: cholesterol acyltransferase and pseudocholinesterase in liver disease and hyperlipoproteinemia. Clin Chim Acta. 1978; 85: 73-9.
71. Valle AM, Radić Z, Rana BK, Whitfield JB, O'Connor DT, Martin NG, et al. The cholinesterases: analysis by pharmacogenomics in man. Chem Biol Interact. 2008; 175: 343-5.
72. Santarpia L, Marra M, Montagnese C, Alfonsi L, Pasanisi F, Contaldo F. Prognostic significance of bioelectrical impedance phase angle in advanced cancer: preliminary observations. Nutrition. 2009; 25: 930-1.
73. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010; 1: 7-8.